TP53 and acute myeloid leukemia: In this study, we found that although AML cells carrying p53 mutation or deletion seemed less sensitive to ABT-199 or TPL than those with wild-type p53, the regimen combining TPL and ABT-199 markedly induced apoptosis and displayed a significantly increased antitumor activity in AML regardless of p53 status.